HCV基因异质性及其宿主基因多态性

聂永红; 许春梅

doi:10.3969/j.issn.1001-5256.2013.10.019

HCV基因异质性及其宿主基因多态性

DOI: 10.3969/j.issn.1001-5256.2013.10.019

金昌市疾病预防控制中心

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2899
- HTML全文浏览量: 9
- PDF下载量: 629
- 被引次数: 0
出版历程
- 收稿日期: 2012-12-07
- 出版日期: 2013-10-20

HCV genetic heterogeneity and its host genetics

Jinchang Center for Disease Control and Prevention

摘要

摘要: 丙型肝炎的进展、严重程度、治疗反应性差异不仅与病毒的遗传多样性有关,而且与宿主IL-28B、IP-10、ITPA基因多态性有关。分别介绍了HCV基因多态性和宿主基因单核苷酸多态性的分子流行病学、临床和治疗学方面的研究进展,提出迫切需要可靠的有关病毒及宿主的相关分子流行病学数据,以协助决策HCV筛检等公共卫生问题,降低丙型肝炎全球发病率和病死率。
- 肝炎,丙型 /
- 肝炎病毒,丙型 /
- 遗传异质性 /
- 遗传学
Abstract: Hepatitis C represents a major worldwide public health problem. Studies have shown that both genetic diversity of hepatitis C virus ( HCV) and genetic polymorphisms of IL- 28B, ITPA, and IP- 10 in the host are implicated in the progression of hepatitis C, treatment response, and adverse effects. The research advances in the molecular epidemiology and clinical and therapeutic interventions of HCV genetic heterogeneity and single nucleotide polymorphisms in its host are reviewed. It is suggested that there is a pressing need for reliable data on the molecular epidemiology of HCV and its host, which will assist in the decision making of public health issues and reduce the morbidity and mortality of hepatitis C worldwide.
- hepatitis C /
- hepatitis C virus /
- genetic heterogeneity /
- genetics

HTML全文

参考文献(39)

[1]MUHLBERGER N, SCHWARZER R, LETTMEIER B, et al.HCV-related burden of disease in Europe:a systematic assessment of incidence, prevalence, morbidity, and mortality[J].BMC Public Health, 2009, 9:34.

[2]GOLEMBA MD, DI LELLO FA, BESSONE F, et al.High prevalence of hepatitis C virus genotype 1b infection in a small town of Argentina.Phylogenetic and Bayesian coalescent analysis[J].PLoS One, 2010, 5 (1) :e8751.

[3]SWAIN MG, LAI MI, SHIFFMAN ML, et al.A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin[J].Gastroenterology, 2010, 139 (5) :1593-1601.

[4]THURSZ M, YEE L, KHAKOO S.Understanding the host genetics of chronic hepatitis B and C[J].Semin Liver Dis, 2011, 31 (2) :115-127.

[5]XIA WJ, YE X, FU YS, et al.Study on association between hepatitis C-6a and HLA-Ⅰallele in Guangzhou area[J].Chin J Immunol, 2011, 27 (4) :330-333. (in Chinese) 夏文杰, 叶欣, 付涌水, 等.广州地区人类白细胞抗原-Ⅰ类与丙型肝炎病毒-6a型感染相关性的研究[J].中国免疫学杂志, 2011, 27 (4) :330-333.

[6]MURPHY D, CHAMBERLAND J, DANDAVINO R, et al.A new genotype of hepatitis C virus originating from central Africa[J].Hepatology, 2007, 46 (Suppl 1) :623a.

[7]GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.

[8]SARRAZIN C, SUSSER S, DOEHRING A, et al.Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients[J].J Hepatol, 2011, 54 (3) :415-421.

[9]ANDRZEJ C, MONIKA BJ, IWONA SK, et al.IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C[J].World J Gastroenterol, 2012, 18 (35) :4892-4897.

[10]SUPPIAH V, MOLODVAN M, AHIENSTIEL G, et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nature Genetics, 2009, 4 (10) :1100-1104.

[11]TANAKA Y, NISHIDA N, SUGIYAMA M, et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nature Genetics, 2009, 41 (10) :1105-1109.

[12]RAUCH A, KUTALIK Z, DESCOMBES P, et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology, 2010, 138 (4) :1338-1345.

[13]KAWAOKA T, HAYES CN, OHISHI W, et al.Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b[J].J Hepatol, 2011, 54 (3) :408-414.

[14]EURICH D, BOAS-KNOOP S, RUEHI M, et al.Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation[J].Liver Transplantation, 2011, 17 (3) :289-298.

[15]FRED P, JONATHAN MC, BRUCE R, et al.Boceprevir for untreated chronic HCV genotype 1 infection[J].N Engl J Med, 2011, 364 (13) :1195-1206.

[16]JACOSON IM, CATLETT I, MARCELLIN P, et al.Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial[J].J Hepatol, 2011, 54 (Suppl 1) :s542-s543.

[17]JENSEN DM, PLO S.IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C:ten years too late?[J].Liver Int, 2012, 32 (Suppl 1) :S74-S78.

[18]THOMAS DL, THIO CL, MARTIN MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.

[19] RAUCH A, KUTALIK Z, DESCOMBES P, et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology, 2010, 138 (4) :1338-1345.

[20]CONG R, TONG XF, LIU SD, et al.Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus[J].J Capit Med Univ, 2012, 33 (3) :326-329.丛瑞, 佟小非, 刘三都, 等.白细胞介素28B (IL-28B) 基因多态性与丙型肝炎病毒 (HCV) 感染者自发清除的相关性[J].首都医科大学学报, 2012, 33 (3) :326-329.

[21]LIU L, FISHER BE, THOMAS DL, et al.Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution[J].Hepatology, 2012, 55 (6) :1684-1691.

[22]BES M, SAULEDA S, CAMPOS-VARELA I, et al.IL28B genetic variation and hepatitis C virus specific CD4+T-cell responses in anti-HCV-positive blood donors[J].J Viral Hepatitis, 2012, 19 (12) :867-871.

[23]BOCHUD PY, BIBERT S, KUTALIK Z, et al.IL28B alleles associated with poor hepatitis C (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotype[J].Hepatology, 2012, 55 (2) :384-394.

[24]CONG R, TONG XF, SUN YM, et al.Association between IL-28B gene polymorphisms and liver fibrosis in patients with chronic hepatitis C[J].Infect Dis Infor, 2012, 25 (2) :93-95.丛瑞, 佟小非, 孙亚朦, 等.IL-28B基因多态性与慢性丙型肝炎患者肝纤维化的相关性研究[J].传染病信息, 2012, 25 (2) :93-95.

[25]ROMERO AI, AGGING ML, WESTIN J, et al.Interferon (IFN) -gamma-inducible protein-10:association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha2a and ribavirin for chronic hepatitis C virus infection[J].J Infect Dis, 2006, 194 (7) :895-903.

[26]ASKARIEH G, ALSIO A, PUGNALE P, et al., Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C[J].Hepatology, 2010, 51 (5) :1523-1530.

[27]ASKARIEH G, ALSIO A, PUGNALE P, et al.Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C[J].Hepatology, 2010, 51 (5) :1523-1530.

[28]FATTOVICH G, COVOLO L, BIBERT S, et al.IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C[J].Aliment Pharmacol Ther, 2011, 33 (10) :1162-1172.

[29]ZAMPINO R, INGROSSO D, DURANTE-MANGONI E, et al.Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3infected patients[J].J Viral Hepat, 2008, 15 (10) :740-746.

[30]VALENTI L, RUMI M, GALMOZZI E, et al.Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C[J].Hepatology, 2011, 53 (3) :791-799.

[31]KNAPP S, WARSHOW U, HEGAZY D, et al.Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus[J].Hepatology, 2010, 51 (4) :1168-1175.

[32]VIDAL-CASTINEIRA JR, LOPEZ-VAZQUEZ A, DIAZ-PENA R, et al.Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection[J].J Virol, 2009, 84 (1) :475-481.

[33]AHLENSTIEL G, MARTIN MP, GAO X, et al.Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses[J].J Clin Invest, 2008, 118 (3) :1017-1026.

[34]AHLENSTIEL G, MARTIN MP, GAO X, et al.Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses[J].J Clin Invest, 2008, 118 (3) :1017-1026.

[35]ISHIDA C, LKEBUCHI Y, OKAMOTO K, et al.Functional gene polymorphisms of interleukin-10 are associated with liver disease progression in Japanese patients with hepatitis C virus infection[J].Inter Med, 2011, 50 (7) :659-666.

[36]FELLAY J, THOMPSON AJ, Ge D, et al.ITPA gene variants protect against anemia in patients treated for chronic hepatitis C[J].Nature, 2010, 464 (7287) :405-408.

[37] THOMPSON AJ, SANTORO R, PIAZZOLLA V, et al.Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR[J].Hepatology, 2011, 53 (2) :389-395.

[38]THOMPSON AJ, SANTORO R, PIAZZOLLA V, et al.Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR[J].Hepatology, 2011, 53 (2) :389-395.

[39]OCHI H, MAEKAWA T, ABE H, et al.ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients[J].Gastroenterology, 2010, 139 (4) :1190-1197.

施引文献

资源附件(0)

访问统计